Southern Research Institute

The University of North Carolina at Chapel Hill

Vanderbilt University

The Uab Research Foundation

John Phillip Tillotson

Corinne E Augelli-Szafran

Ralph Baric

Bini Mathew

Ashish Kumar Pathak

Syed Kaleem Ahmed

Omar Moukha-Chafiq

Timothy Patrick Sheahan

Mark R Denison

Terry Smalley

Kevin Jay Rodzinak

Amy Catherine Sims

Shilpa Dutta

Robert Hunter

The present disclosure is concerned with substituted uracil compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders associated with the presence of a premature termination codon such as, for example, cystic fibrosis, Duchenne muscular dystrophy, aniridia, Becker muscular dystrophy, spinal muscular atrophy, Hurler syndrome, hemophilia, epidermolysis bullosa (e.g., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Uracil derivatives for stimulating read-through of premature termination codons

The present disclosure is concerned with substituted phenyl ethynyl pyridine carboxamide compounds, pharmaceutical compositions comprising the compounds, and methods of treating viral infections due to a Coronavirus such as, for example, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus

Growing community of inventors

Birmingham, AL, United States of America

John Phillip Tillotson